A multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 [alferminogene tadenovec; Generx] in patients with stable angina.

Trial Profile

A multicenter, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of Ad5FGF-4 [alferminogene tadenovec; Generx] in patients with stable angina.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Jun 2014

At a glance

  • Drugs Alferminogene-tadenovec (Primary)
  • Indications Angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms AGENT-3
  • Most Recent Events

    • 24 Jun 2014 According to Taxus Cardium Pharmaceuticals Group media release, a pooled analysis of the SPECT results of the interim ASPIRE data with the AGENT Phase 2 (700026806, 700016778) study data shows that patients treated with Generx have a 25% improvement in RPDS that is also statistically significant compared to the pooled control groups (p=0.005, n=63).
    • 23 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top